Larry Corey, MD


Larry Corey, MD

President and Director Emeritus
Fred Hutch

Vaccine and Infectious Disease Division, Fred Hutch

Clinical Research Division, Fred Hutch

Public Health Sciences Division, Fred Hutch

Fax: 206.667.1188
Mail Stop: E3-300

Dr. Larry Corey is an internationally renowned expert in virology, immunology and vaccine development, and the former president and director of Fred Hutch. His research focuses on herpes viruses, HIV, the novel coronavirus and other viral infections, including those associated with cancer. He is principal investigator of the HIV Vaccine Trials Network, or HVTN, which conducts studies of HIV vaccines at over 80 clinical trial sites in 16 countries on five continents. Under his leadership, the HVTN has become the model for global, collaborative research. Dr. Corey is also the principal investigator of the Fred Hutch-based operations center of the COVID-19 Prevention Network, or CoVPN, and co-leads the network’s vaccine testing pipeline. Dr. Corey’s own laboratory group at Fred Hutch studies how immune cells control herpes simplex virus. Their goal is to make a vaccine that will reduce the virus’s reactivation. In the early 1980s, he worked with future Nobel laureate Dr. Gertrude Elion in the development of acyclovir as the first effective therapy for genital herpes. As director of the AIDS Clinical Trials Group, he led the organization that eventually proved combination antiretroviral treatments could control HIV. The team also demonstrated that these drugs could reduce transmission of HIV from mothers to their infants. His research also showed that HIV-1 replicates in blood early in disease, emphasizing the importance of early therapy.

Teaching and Mentoring Interests


Viral immunology

Development of novel therapies for viral infections

Other Appointments & Affiliations

Professor, Medicine and Laboratory Medicine
University of Washington

Principal Investigator
HIV Vaccine Trials Network (HVTN)


University of Michigan Medical School, Ann Arbor, 1971, M.D.

University of Michigan, Ann Arbor, 1967, B.S. (with high distinction)

Research Interests

HIV and herpesvirus vaccine development

Herpes simplex virus type 2 (HSV-2) pathogenesis and the host immune response

Immunotherapeutic approaches to viral infections and cancer

Current Projects

Spatial and functional characterization of tissue resident immune responses at the site of herpesvirus or HIV infection

Development of immunotherapies for HSV and HIV infection; including CAR T cells for treatment for HIV infection

Spatial dynamics and function of adoptively transferred or vaccine induced T cells

Characterization of tissue-based memory B cells and the role antibody effector responses play in chronic viral infections

Use of monoclonal antibodies for the prevention of viral infections

"There is nothing that has impacted the lives of more people than antivirals, especially those for HIV."

—  Dr. Lawrence Corey

Find a Clinical Trial

Dr. Corey in the News

2022 Year in Review

Hutch News - December 12, 2022

Year in Pictures: 2022

Hutch News - December 12, 2022

Dr. Larry Corey receives Alexander Fleming Award

Hutch News - October 21, 2022

COVID-19 Research at Fred Hutch

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email or call 206.667.2210